New England Journal of Medicine (NEJM) on Thursday, as well as the regulator’s briefing document for the vaccine, showed a lack of data on Asian participants, a potential concern considering that Pfizer has asked for a clinical trial waiver in its application for an emergency licence in India.A spokesperson for Pfizer said the term Asians in the data refers to ethnicities across the Asian continent, including Indians.Only 4.3% of the global phase 3 trial participants recruited by the US firm were Asian, while the efficacy rate for the diverse ethnic group was 74.4%.
In contrast, the company’s overall efficacy was 95% for a cohort, which comprised 83% whites, according to the documents published by the US FDA.“We know in the past there have.